Image

Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study

Recruiting
18 - 90 years of age
Both
Phase N/A

Powered by AI

Overview

ULTRA is a multicenter, observational, retrospective registry, enrolling consecutive patients treated with ultrathin coronary DES (coronary stent with strut thickness < 70 um) for coronary bifurcation lesions, left main disease, chronic total coronary occlusion, and in-stent restenosis regardless of their clinical presentation. Target lesion failure (TLF a composite endpoint of cardiovascular death, target vessel myocardial infarction, target lesion revascularization and definite stent thrombosis) will be the primary end point, while its single components will be the secondary ones along with all-cause death, all acute myocardial infarction (excluding peri-procedural AMI), target vessel revascularization and BARC major bleedings (BARC 3-5). Due to the retrospective, observational nature of the registry, no formal sample size estimation is required. Patients complying with detailed inclusion criteria and with a minimum follow up of 6 months will be enrolled.

Eligibility

Inclusion Criteria:

  • age > 18 years old
  • Unprotected left main stenosis
  • Bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm)
  • Chronic total coronary occlusion
  • In-stent restenosis

Treated with the following devices:

  • Orsiro
  • Mistent
  • BioMime
  • Supraflex Cruz

Exclusion Criteria:

  • patients died during the index revascularization procedure

Study details

Coronary Artery Disease, Coronary Stenosis, Stent Restenosis, Left Main Coronary Artery Disease, Chronic Total Occlusion of Coronary Artery

NCT05205148

Azienda Ospedaliera Città della Salute e della Scienza di Torino

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.